Evidence map›Paper›PMID 39172301›Full record

ArticleAnnals of surgical oncology2024

Hepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation.

Abraham J Matar, Kailey M Oppat, Frances J Bennett, Emilie A K Warren, Chase J Wehrle, Zhihao Li, Luckshi Rajendran, Zachary P Rokop, Chandrashekhar Kubal, Ben E Biesterveld and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Abraham J MatarEmory University, Atlanta, GA, USA. matar033@umn.edu.ORCID http://orcid.org/0000-0001-8453-295X
Kailey M OppatEmory University, Atlanta, GA, USA.
Frances J BennettEmory University, Atlanta, GA, USA.
Emilie A K WarrenEmory University, Atlanta, GA, USA.
Chase J WehrleCleveland Clinic, Cleveland, OH, USA.
Zhihao LiAjmera Transplant Center and HPB Surgical Oncology, University Health Network, Toronto, ON, Canada.
Luckshi RajendranAjmera Transplant Center and HPB Surgical Oncology, University Health Network, Toronto, ON, Canada.
Zachary P RokopIndiana University Health, Indianapolis, IN, USA.
Chandrashekhar KubalIndiana University Health, Indianapolis, IN, USA.
Ben E BiesterveldUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
David P FoleyUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Mayumi MaedaStanford University Medical Center, Palo Alto, CA, USA.
Mindie H NguyenStanford University Medical Center, Palo Alto, CA, USA.
Beth ElinoffUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abhinav HumarUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Dimitrios MorisDuke University School of Medicine, Durham, NC, USA.
Debra SudanDuke University School of Medicine, Durham, NC, USA.
John KleinUniversity of Southern California, Los Angeles, CA, USA.
Juliet EmamaulleeUniversity of Southern California, Los Angeles, CA, USA.
Vatche AgopianDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Parsia A VagefiUT Southwestern Medical Center, Dallas, TX, USA.
Shukri H A DualehUniversity of Michigan, Ann Arbor, MI, USA.
Christopher J SonnendayUniversity of Michigan, Ann Arbor, MI, USA.
Gonzalo SapisochinAjmera Transplant Center and HPB Surgical Oncology, University Health Network, Toronto, ON, Canada.
Federico N AucejoCleveland Clinic, Cleveland, OH, USA.
Shishir K MaithelEmory University, Atlanta, GA, USA.

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

backgroundLiver transplantation (LT) is the treatment of choice for end-stage liver disease and certain malignancies such as hepatocellular carcinoma (HCC). Data on the surgical management of de novo or recurrent tumors that develop in the transplanted allograft are limited. This study aimed to investigate the perioperative and long-term outcomes for patients undergoing hepatic resection for de novo or recurrent tumors after liver transplantation.

methodsThe study enrolled adult and pediatric patients from 12 centers across North America who underwent hepatic resection for the treatment of a solid tumor after LT. Perioperative outcomes were assessed as well as recurrence free survival (RFS) and overall survival (OS) for those undergoing resection for HCC.

resultsBetween 2003 and 2023, 54 patients underwent hepatic resection of solid tumors after LT. For 50 patients (92.6 %), resection of malignant lesions was performed. The most common lesion was HCC (n = 35, 64.8 %), followed by cholangiocarcinoma (n = 6, 11.1 %) and colorectal liver metastases (n = 6, 11.1 %). The majority of the 35 patients underwent resection of HCC did not receive any preoperative therapy (82.9 %) or adjuvant therapy (71.4 %), with resection their only treatment method for HCC. During a median follow-up period of 50.7 months, the median RFS was 21.5 months, and the median OS was 49.6 months.

conclusionHepatic resection following OLT is safe and associated with morbidity and mortality rates that are comparable to those reported for patients undergoing resection in native livers. Hepatic resection as the primary and often only treatment modality for HCC following LT is associated with acceptable RFS and OS and should be considered in well selected patients.

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalAdolescentAdultAgedChildCholangiocarcinomaFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisDe novo tumorsHepatocellular carcinomaLiver transplantationRecurrence

Identifiers

PMID39172301
PMCPMC11931599

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.